We are proud to announce that ReCode’s lead therapeutic candidate, RCT1100, has received U.S. FDA Orphan Drug Designation for the treatment of primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene. PCD is a rare genetic lung disorder that currently has no FDA-approved treatments, so receiving this designation is an important recognition for the PCD patient community. We want to thank the entire ReCode team for their continued persistence in unlocking the potential of precision mRNA and gene correction therapeutics. We also thank the PCD Foundation, all people living with PCD, and their families for providing the feedback and insights that shape our research and power our progress. Learn more about RCT1100 here: https://lnkd.in/gv647SZs
ReCode Therapeutics
Biotechnology Research
Powering the next wave of genetic medicines through superior delivery
About us
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
- Website
-
https://recodetx.com/
External link for ReCode Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Menlo Park, California & Dallas, Texas
- Type
- Privately Held
- Founded
- 2015
- Specialties
- RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology
Locations
-
Primary
Menlo Park, California & Dallas, Texas, US
Employees at ReCode Therapeutics
Updates
-
Find out where we’ll be in August — check our latest calendar here: https://lnkd.in/gsWyhr8V
-
On World Lung Cancer Day, we honor the resilience of those affected by lung cancer and the dedication of the families, healthcare professionals, and researchers who support them along their care journey. From the Lung Cancer Foundation of America: “Since its inception in 2012, World Lung Cancer Day has been observed every year on August 1 to raise awareness of lung cancer issues and magnify the need for more lung cancer research funding.” At ReCode Therapeutics, our mission is to power the next wave of genetic medicines through superior delivery. While we focus on innovative treatments for cystic fibrosis and primary ciliary dyskinesia, we share the same fundamental goal as those advocating for lung cancer awareness: ensuring that every medical breakthrough is accessible. All medical research should strive for inclusivity, and all medical organizations should advocate for bringing their solutions to everyone in need. #WLCD24 #PatientFirst
-
We are proud to support Emily's Entourage and the CF patient community.
At Emily’s Entourage, our singular goal is to speed lifesaving breakthroughs and a cure for the final 10% of the CF community. The support of our annual sponsors enables us pursue that mission. We extend our heartfelt gratitude to ReCode Therapeutics for their 2024 Tier 3 Annual Sponsorship in 2024! Their passionate, continued support of EE and the #cysticfibrosis community helps get us closer to achieving that critical goal. We are so deeply appreciative. 💜 🔗 Visit their website >>> https://recodetx.com/ . . . #sponsor #nonprofit #CFcommunity #CFAwareness #CF
-
Our CEO, Shehnaaz Suliman, M.D. (MB ChB), M.B.A., M.Phil., discussed on Locust Walk how we prioritized research for our Selective Organ Targeting (SORT) Lipid Nanoparticle (LNP) platform: “We followed the science. We started in the lungs because no one else had gone there. And also because it’s about as far away […] from the liver as you can go. Showing proof of concept there with a novel formulation that is clearly not the liver de-risks not just the program and the modality, but the overall platform as well.” Utilizing our SORT LNP platform, we are working on therapies to reach all patients, including those for whom existing options are insufficient. Learn more about the next generation of genetic medicine delivery via the link below: https://lnkd.in/gjWyq3MZ
-
ReCode Therapeutics reposted this
If you are a #PCD patient looking to learn more about the clinical trial process, check out this webinar we conducted with the PCD Foundation. In the video below—ReCode's Ramona Doyle MD, presents useful information on what #ClinicalTrials involve and what you can expect if you decide to participate in one. Video link: https://lnkd.in/gBVustTs To learn more about primary ciliary dyskinesia, visit: https://thinkpcd.com/
An Introduction to Clinical Trials- Recode Therapeutics
https://www.youtube.com/
-
Introducing #futuretalent, Lila Motamedi! ⭐ Join us in hearing about her #internship experience in ReCode's Clinical Operations department and what she's learned along the way. With #TeamReCode, Lila is shaping her career future in real time. Let's celebrate her accomplishments to date as we look toward the next chapters of Lila's story!
-
If you are a #PCD patient looking to learn more about the clinical trial process, check out this webinar we conducted with the PCD Foundation. In the video below—ReCode's Ramona Doyle MD, presents useful information on what #ClinicalTrials involve and what you can expect if you decide to participate in one. Video link: https://lnkd.in/gBVustTs To learn more about primary ciliary dyskinesia, visit: https://thinkpcd.com/
An Introduction to Clinical Trials- Recode Therapeutics
https://www.youtube.com/
-
Our lead therapeutic candidate, RCT1100, has received U.S. FDA Orphan Drug Designation for the treatment of primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene. PCD is a rare genetic lung disorder with no FDA-approved treatments, making this designation significant for the PCD community. RCT1100 is an investigational mRNA-based therapeutic that targets gene mutations crucial for ciliary movement. Delivered as an inhaled therapy, RCT1100 aims to restore ciliary function in affected persons, addressing the root cause rather than merely managing symptoms. We thank #TeamReCode for their persistence, the PCD Foundation, patients, and their families for their invaluable feedback and insights. You can learn more about RCT1100 here: https://recodetx.com/pcd/ #PCD #mRNA #GeneticMedicine
-
Are you interested in powering the next wave of genetic medicines with ReCode Therapeutics? With our cutting-edge SORT LNP delivery technology, we're creating new pathways in precision genetic medicine. We are looking for collaborators as passionate as we are about transforming patient care through innovative research and applications. Discover more about partnership opportunities below: https://lnkd.in/g_ZZF8wF #GeneticMedicine #PrecisionHealthcare #InnovationPartnerships